Financial guidance 2020
MorphoSys published its financial guidance 2020 on March 18, 2020.
|
in € million |
Guidance 2020 |
Results 2019 |
|---|---|---|
| Group Revenues | 280 to 290 | 71.8 |
| R&D expenses | 130 to 140 | 108.4 |
| Group EBIT | -15 to 5 | - 107.9 |
This guidance does not include revenues generated from tafasitamab and revenues from future collaborations and/or licensing agreements. Revenues are expected to include royalty income from Tremfya® of €37 to €42 million. The guidance is based on constant currency exchange rates and does not include any contributions from tafasitamab revenues and any effects from potential in-licensing or co-development deals for new development candidates. The operational and financial guidance does not include a potential impact of the ongoing global COVID-19 crisis on MorphoSys’ business operations including but not limited to the Company’s supply chain, clinical trial conduct, as well as timelines for regulatory and commercial execution.
